JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Aandelen Lijst・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Gesloten

SectorGezondheidszorg

5.2 1.96

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.13

Max

5.25

Belangrijke statistieken
By Trading Economics
Inkomsten	2.1M -7.5M
Winstmarge	-33,241.667
Werknemers	15
EBITDA	4.5M -5.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+14.72% upside

Dividenden
By Dow Jones
Volgende Winsten	13 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	80M 326M
Vorige openingsprijs	3.24
Vorige sluitingsprijs	5.2

Nieuwssentiment

By Acuity

26%

74%

51 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

1.19 / 1.33 Steun & Weerstand

Galectin Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 okt 2025, 18:41 UTC

Winsten

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 okt 2025, 18:31 UTC

Winsten

Correction to Procter & Gamble to Focus on Innovation

24 okt 2025, 16:25 UTC

Belangrijke Marktbewegers

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 okt 2025, 21:24 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 okt 2025, 21:24 UTC

Marktinformatie

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 okt 2025, 21:07 UTC

Winsten

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 okt 2025, 20:58 UTC

Winsten

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 okt 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 20:40 UTC

Winsten

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 okt 2025, 20:24 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:23 UTC

Winsten

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 okt 2025, 20:13 UTC

Winsten

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 20:07 UTC

Marktinformatie

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 okt 2025, 19:40 UTC

Marktinformatie

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 okt 2025, 19:35 UTC

Marktinformatie

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 okt 2025, 19:33 UTC

Winsten

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 okt 2025, 19:29 UTC

Marktinformatie

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 okt 2025, 18:52 UTC

Winsten

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:41 UTC

Winsten

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 okt 2025, 18:03 UTC

Winsten

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 okt 2025, 18:02 UTC

Winsten

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 okt 2025, 18:00 UTC

Marktinformatie

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 okt 2025, 16:57 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 okt 2025, 16:54 UTC

Marktinformatie

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 okt 2025, 16:44 UTC

Marktinformatie

Winsten

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 okt 2025, 16:39 UTC

Marktinformatie

Winsten

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 okt 2025, 16:33 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:23 UTC

Winsten

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 okt 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

24 okt 2025, 16:07 UTC

Winsten

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer Vergelijking

Prijswijziging

Galectin Therapeutics Inc Prognose

Koersdoel

By TipRanks

14.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6 USD 14.72%

Hoogste 6 USD

Laagste 6 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Galectin Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Galectin Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.19 / 1.33Steun & Weerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

51 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.